Completed PHASE1 INTERVENTIONAL 1-arm NCT00084422

N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

A Phase I Study Of CEP-701 In Patients With Refractory Neuroblastoma (IND # 67,722)

Sponsor: National Cancer Institute (NCI)

Updated 7 times since 2017 Last updated: Apr 6, 2023 Started: Aug 31, 2003 Primary completion: Sep 30, 2009 Completion: Feb 28, 2011

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00084422, this PHASE1 trial focuses on Neuroblastoma and remains completed. Sponsored by National Cancer Institute (NCI), it has been updated 7 times since 2003, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.

Status Flow

Change History

7 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
May 2023 — Jul 2024 [monthly]

Completed PHASE1
Jan 2021 — May 2023 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

Feb 2017 — Jun 2018 [monthly]

Completed PHASE1
Jan 2017 — Feb 2017 [monthly]

Completed PHASE1

First recorded

Aug 2003

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

National Cancer Institute (NCI)
New Approaches to Neuroblastoma Therapy Consortium

Data source: New Approaches to Neuroblastoma Therapy Consortium

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Atlanta, United States , Boston, United States , Chicago, United States , Cincinnati, United States , Los Angeles, United States , New York, United States , Palo Alto, United States , Philadelphia, United States , San Francisco, United States and 2 more locations